Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. - Wikidata - wikimedia - TriplyDB

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

http://www.wikidata.org/entity/Q33384665

about

Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Imaging of HCC-Current State of the Art Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma Treatment of hepatocellular carcinoma: Steps forward but still a long way to go Systemic therapy of hepatocellular carcinoma: current status and future perspectives New approaches for precise response evaluation in hepatocellular carcinoma Molecular classification and novel targets in hepatocellular carcinoma: recent advancements ¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Multiparametric MR Imaging in Abdominal Malignancies.Normalization of the vasculature for treatment of cancer and other diseases.A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience.Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells.Molecular mechanisms of resistance to tumour anti-angiogenic strategies Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models A multidisciplinary approach to the management of hepatocellular carcinoma.Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens

P2860

Q26752752-671BFD9C-D49A-47E6-BF42-06747512C468 Q26766689-784042B5-463C-40D5-8F24-27593C7252D0 Q26768463-A368C695-8D10-4BB3-AEC1-5E6F9519EBC8 Q26783895-8DE999B2-2AF8-436D-99E9-AB397302B220 Q26784218-B14A5D0E-77C9-471F-BD8A-29E69B1F72A1 Q26799458-4B08139E-02D3-40DC-B46E-60E5D2514807 Q26823035-E84C2CE3-33BE-47DA-9A6B-FCF78D2F70F1 Q26823523-300DA22A-EB18-4B08-9951-E9966224362C Q26865456-899B04D6-90A1-47C8-BD26-9CB39142C521 Q26865844-E7E4ED02-F9D8-475F-B5B3-551BDC3CE0BD Q26866367-253EB51A-09A8-403C-B049-1471D3C7924A Q28383646-CCE0C093-DF6A-4EF6-9528-A0081E1B9C0B Q28687190-87C4EF62-F4BD-4E4B-8AFE-C206CCCA5F63 Q30240170-870BF3D4-75CD-4918-A5B5-35DE66C7BFBF Q30364605-2C8429C0-A069-4A8A-A029-4AA6A281B602 Q30471456-AF5DFA3B-81AA-4733-897C-82E6A060B398 Q30493217-7EE832CD-B5D8-4693-9B40-EE1E174DA10B Q30542073-4F5AA059-4E8C-46EB-BDAA-DD1ECDCABA45 Q30559275-680BCC53-64D0-4D32-BDA5-950D6ED0555B Q31030824-11FB7678-ACE6-4E8F-BE24-9069CA88154E Q31119452-72F94D43-856B-4B21-8007-18A7F98FF588 Q33390267-7A23516E-91A5-49EB-9CF3-FA81BA9C3F10 Q33391770-667E61D0-F2EE-4745-9CEE-D388D66F546B Q33395853-0C39F3A9-B87D-49B3-BCDF-59A643B4F289 Q33413742-3D1F4F17-4CCD-4E7D-B321-184508882627 Q33496309-B57A6940-47C8-4093-BA5F-4C8EB8CB06FB Q33559444-F6997FEF-37A8-4BA0-9A29-C93352606924 Q33627739-65BA6A41-3FF1-41D1-98B3-54DC9BC59D7B Q33630819-22AFC9FD-1DFF-41A8-8AD8-3DC34F8BAFA1 Q33686817-FF4F947E-9E1D-4E68-9B13-747464F2B49E Q33713444-08F243EE-2703-4988-BFF1-F0EF3E16B236 Q33718025-BCA43603-D809-4BBA-8133-96BAD8011AE3 Q33757046-7DE13B67-C74C-4137-B72A-7F94C4A2D9B6 Q33808012-BC2FB16E-0DCE-4055-98E9-263453621768 Q33811126-539B4B1A-9A97-4EAB-8900-D6EBDF800A4E Q33916361-B63C0FDF-3C56-468C-AA81-DB11A69D0E76 Q33920350-748159A7-1373-4283-A421-C8B798257D20 Q33990834-9D762F3E-F855-4E2C-996A-BB4DD01CBC51 Q34131801-C3029B7A-4799-4ECD-9EED-964005432BD7 Q34309960-995D8D28-F3AA-45FF-86A6-80E0005261C4

P2860

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

http://www.wikidata.org/entity/Q33384665

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Efficacy, safety, and potentia ...... r carcinoma: a phase II study.

@ast

Efficacy, safety, and potentia ...... r carcinoma: a phase II study.

@en

type

label

Efficacy, safety, and potentia ...... r carcinoma: a phase II study.

@ast

Efficacy, safety, and potentia ...... r carcinoma: a phase II study.

@en

prefLabel

Efficacy, safety, and potentia ...... r carcinoma: a phase II study.

@ast

Efficacy, safety, and potentia ...... r carcinoma: a phase II study.

@en

P1433

Q33384665-20DA29B8-4059-4EFC-A00E-96EBF922F0B2

P1476

Q33384665-9C6B7918-6305-4F87-9BE6-01246D63EC7C

P2093

Q33384665-17EE5D0D-A5D3-41AF-AFEB-9D913EF49C77

Q33384665-36AE0317-7D10-47DB-A3EF-F00C7221CFCE

Q33384665-475A3C40-0D35-4A1B-A09B-3A8F3176F899

Q33384665-486C9F26-03F8-4544-A394-51AC91D59635

Q33384665-5AB28B77-D924-4C67-80A9-DAD659CEF802

Q33384665-905223E2-C055-4F80-BE53-B4B780AB4834

Q33384665-9669C9DD-5686-4722-AD5F-06DA81E1A30B

Q33384665-A40491C3-DBEA-4C56-B323-9CF2C34B2C96

Q33384665-A48EE791-D6BF-4E92-92CD-365830F650A7

Q33384665-B8E07C73-C89D-4D28-91B7-1DF191F1A150

P2860

Q33384665-01CAA59D-3515-4B8E-8277-398EB1D757CB

Q33384665-02184D3E-3A63-402A-8C1E-954E6826B27C

Q33384665-0F603E5C-D43D-42A6-AD20-7B28446B8ABC

Q33384665-22234812-7D61-499A-9AA5-A6AF4372D27F

Q33384665-23B402F4-3225-4BA8-A458-8B2C1D900138

Q33384665-31E5352C-FBC3-46F7-87D7-36C7889DEDF7

Q33384665-33FB944C-3CA3-4357-B91D-4521E6CF8C70

Q33384665-3C5776E2-110F-4886-A170-EDB387FBE53E

Q33384665-3EF34E4E-DE24-45BC-A32D-142AD2485734

Q33384665-4585CC8B-B112-477D-AE1E-0B4A0E8E1E46

P304

Q33384665-8436E9C5-CBD5-4B45-BB9C-F11712B32A28

P31

Q33384665-833F965F-481B-499E-833A-E97A23B77513

P356

Q33384665-C2A78039-4A14-4C99-99E7-22BD199912AB

P407

Q33384665-74B8447F-996D-4624-B3AE-90132461B882

P433

Q33384665-C00BF21D-17AF-498C-A73D-E372B102FA66

P478

Q33384665-A545613C-4DF3-4845-84E9-353471D6F7D5

P50

Q33384665-7050F88F-DEA8-401E-9C52-E02357D83D1A

Q33384665-881016CC-A8B6-4F3A-8D8E-3CBE2D593829

Q33384665-C403EF3B-1639-4954-91B5-0F5A36397663

P577

Q33384665-A5C2E1E2-D61D-4B71-B7EE-CFEF9FB91BD7

P698

Q33384665-3E5319CB-FDF6-4306-9BC0-8D41B31E01EC

P921

Q33384665-1267E49B-C7FE-41EC-A268-6A0D1C4F9CA2

P932

Q33384665-1C1DC892-38A6-4D6A-B936-C417BC2D014F

P356

JCO.2008.20.9908

P1433

Journal of Clinical Oncology

P1476

Efficacy, safety, and potentia ...... r carcinoma: a phase II study.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Aram F Hezel

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

David P Ryan

http://www.w3.org/2001/XMLSchema#string

Dushyant V Sahani

http://www.w3.org/2001/XMLSchema#string

Emmanuelle di Tomaso

http://www.w3.org/2001/XMLSchema#string

Eunice L Kwak

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Clark

http://www.w3.org/2001/XMLSchema#string

Johanna Lahdenranta

http://www.w3.org/2001/XMLSchema#string

Lawrence S Blaszkowsky

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

The role of myeloid cells in the promotion of tumour angiogenesis

Paradoxical roles of the immune system during cancer development

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

P304

3027-3035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.9908

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Charles S. Fuchs

Jeffrey A Meyerhardt

P577

2009-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19470923

http://www.w3.org/2001/XMLSchema#string

P921

P932

2702235

http://www.w3.org/2001/XMLSchema#string